Literature DB >> 24476696

Comparing the impact of two concurrent infectious disease outbreaks on The Netherlands population, 2009, using disability-adjusted life years.

R J Brooke1, A Van Lier2, G A Donker3, W Van Der Hoek2, M E E Kretzschmar1.   

Abstract

In 2009 two notable outbreaks, Q fever and the novel influenza A(H1N1)pdm09, occurred in The Netherlands. Using a composite health measure, disability-adjusted life years (DALYs), the outbreaks were quantified and compared. DALYs were calculated using standardized methodology incorporating age- and sex-stratified data in a disease progression model; years lost due to disability and years of life lost were computed by outcome. Nationally, influenza A(H1N1)pdm09 caused more DALYs (24 484) than Q fever (5797). However, Q fever was 8·28 times more severe [497 DALYs/1000 symptomatic cases (DP1SC)] than A(H1N1)pdm09 (60 DP1SC). The A(H1N1)pdm09 burden is largely due to mortality while the Q fever burden is due primarily to long-term sequelae. Intervention prioritization for influenza should support patients in a critical condition while for Q fever it should target immediate containment and support for patients with long-term sequelae. Burden estimates provide guidance for focusing intervention options during outbreaks of infectious diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24476696      PMCID: PMC9151298          DOI: 10.1017/S0950268813003531

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  31 in total

1.  Surveillance of respiratory pathogens and influenza-like illnesses in general practices - The Netherlands, winter 1997-98.

Authors:  M.L.A. Heijnen; J.W. Dorigo-Zetsma; A.I.M. Bartelds; B Wilbrink; M.J.W Sprenger
Journal:  Euro Surveill       Date:  1999-07

2.  The 2007–2010 Q fever epidemic in The Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming.

Authors:  Frederika Dijkstra; Wim van der Hoek; Nancy Wijers; Barbara Schimmer; Ariene Rietveld; Clementine J Wijkmans; Piet Vellema; Peter M Schneeberger
Journal:  FEMS Immunol Med Microbiol       Date:  2012-02

3.  Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom.

Authors:  C R Meier; P N Napalkov; Y Wegmüller; T Jefferson; H Jick
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-11       Impact factor: 3.267

4.  Post-infection fatigue syndrome following Q fever.

Authors:  J G Ayres; N Flint; E G Smith; W S Tunnicliffe; T J Fletcher; K Hammond; D Ward; B P Marmion
Journal:  QJM       Date:  1998-02

5.  Follow-up of 686 patients with acute Q fever and detection of chronic infection.

Authors:  Wim van der Hoek; Bart Versteeg; Jamie C E Meekelenkamp; Nicole H M Renders; Alexander C A P Leenders; Ineke Weers-Pothoff; Mirjam H A Hermans; Hans L Zaaijer; Peter C Wever; Peter M Schneeberger
Journal:  Clin Infect Dis       Date:  2011-06-15       Impact factor: 9.079

6.  Understanding DALYs (disability-adjusted life years).

Authors:  C J Murray; A K Acharya
Journal:  J Health Econ       Date:  1997-12       Impact factor: 3.883

7.  Identification of risk factors for chronic Q fever, the Netherlands.

Authors:  Linda M Kampschreur; Sandra Dekker; Julia C J P Hagenaars; Peter J Lestrade; Nicole H M Renders; Monique G L de Jager-Leclercq; Mirjam H A Hermans; Cornelis A R Groot; Rolf H H Groenwold; Andy I M Hoepelman; Peter C Wever; Jan Jelrik Oosterheert
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

8.  Screening for Coxiella burnetii seroprevalence in chronic Q fever high-risk groups reveals the magnitude of the Dutch Q fever outbreak.

Authors:  L M Kampschreur; J C J P Hagenaars; C C H Wielders; P Elsman; P J Lestrade; O H J Koning; J J Oosterheert; N H M Renders; P C Wever
Journal:  Epidemiol Infect       Date:  2012-06-13       Impact factor: 4.434

9.  Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children.

Authors:  Cees C van den Wijngaard; Liselotte van Asten; Marion P G Koopmans; Wilfrid van Pelt; Nico J D Nagelkerke; Cornelia C H Wielders; Alies van Lier; Wim van der Hoek; Adam Meijer; Gé A Donker; Frederika Dijkstra; Carel Harmsen; Marianne A B van der Sande; Mirjam Kretzschmar
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

10.  Infective endocarditis: too ill to be operated?

Authors:  Bina Rubinovitch; Didier Pittet
Journal:  Crit Care       Date:  2002-03-12       Impact factor: 9.097

View more
  6 in total

1.  Selection of key recommendations for quality indicators describing good quality outbreak response.

Authors:  Evelien Belfroid; Jeannine L A Hautvast; Mirrian Hilbink; Aura Timen; Marlies E J L Hulscher
Journal:  BMC Infect Dis       Date:  2015-03-31       Impact factor: 3.090

2.  Vaccination against Q fever for biodefense and public health indications.

Authors:  Sara Ruiz; Daniel N Wolfe
Journal:  Front Microbiol       Date:  2014-12-16       Impact factor: 5.640

Review 3.  Fatigue following Acute Q-Fever: A Systematic Literature Review.

Authors:  Gabriella Morroy; Stephan P Keijmel; Corine E Delsing; Gijs Bleijenberg; Miranda Langendam; Aura Timen; Chantal P Bleeker-Rovers
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

4.  Climate change effects on airborne pathogenic bioaerosol concentrations: a scenario analysis.

Authors:  J P G van Leuken; A N Swart; P Droogers; A van Pul; D Heederik; A H Havelaar
Journal:  Aerobiologia (Bologna)       Date:  2016-03-24       Impact factor: 2.410

5.  zDALY: An adjusted indicator to estimate the burden of zoonotic diseases.

Authors:  Paul R Torgerson; Simon Rüegg; Brecht Devleesschauwer; Bernadette Abela-Ridder; Arie H Havelaar; Alexandra P M Shaw; Jonathan Rushton; Niko Speybroeck
Journal:  One Health       Date:  2017-11-28

6.  Pulmonary Valve Prosthesis Endocarditis Caused By Coxiella burnetii.

Authors:  Jamila Kremer; Nico Tom Mutters; Matthias Karck; Katharina Last
Journal:  Thorac Cardiovasc Surg Rep       Date:  2018-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.